Testosterone is a hormone that your sex organs mainly produce. Additionally, though data on this ultralong-acting formulation are available with the 1000-mg dose regimen (26), studies with the 750-mg dose (the approved dose in the United States) are also needed. A Luer-Lok syringe is preferred to prevent the needle from disengaging from the syringe during injection considering the viscosity of the solution. Therefore, patient participation and engagement in the selection of testosterone formulation is likely to promote adherence (57). The most frequent events were erythrocytosis (21 men; 7 discontinued), hypertension (19 men; 1 discontinued), and increase in serum prostate-specific antigen of 1.4 ng/mL or greater from baseline (18 men; 13 discontinued) (27). Three patients developed erythrocytosis that resulted in their discontinuation from the study (29). Your provider can assess your body composition and recommend the most appropriate method. Your provider will determine the optimal frequency based on your dose and response. Your provider may adjust your injection frequency or volume when switching to SubQ, as smaller volumes per injection site are typically recommended. ARatio of AUC0-168h of DHT and estradiol to AUC0-168h of serum total T at week 6 of treatment. Serum total A, testosterone; B, 5-dihydrotestosterone; and C, estradiol concentrations after subcutaneous (SC) or intramuscular (IM) administration of 1000 mg of testosterone undecanoate. The ultralong-acting ester testosterone undecanoate has been available for IM injection in Europe and Australia for almost 2 decades, and in the United States since 2014. Mean serum total testosterone was 702 ± 212 ng/dL with a range of 357 to 1377 ng/dL (Fig. 5A). Mean total testosterone concentrations gradually increased from predose values of 224 ng/dL to 374 ng/dL, 479 ng/dL, and 541 ng/dL at weeks 1, 6, and 12, respectively (29) (Fig. 4A). To the contrary, the group receiving the 200-mg IM injection achieved supraphysiologic levels during the first week after the injection. This was confirmed by pharmacokinetic studies that assessed the Cmax and tmax of testosterone in the serum, and the average serum total testosterone concentration during the steady state. Your testosterone doctor can also help you watch for side effects. Testosterone can be administered through intramuscular or subcutaneous injections. Many clinicians and patients report meaningful improvements when therapy is carefully monitored. Several factors can cause a dip in women’s testosterone production. This is especially true when both partners manage their hormone health together. Despite its significance, low testosterone in women remains under-discussed. And, this hormone is vital for their overall health and well-being. NRG Clinic does not practice medicine, employ medical providers, or make clinical treatment decisions. Energy Virtual Medical PA employs the licensed physicians and healthcare practitioners who provide telehealth medical services. Very lean individuals with minimal subcutaneous fat may have difficulty with SubQ injections, as adequate fatty tissue is needed for proper absorption. The more frequent SubQ schedule can help maintain more stable hormone levels. Yes, many patients successfully switch between injection methods. Some research suggests SubQ may provide more stable hormone levels with less peak-to-trough variation, though individual responses vary. Working with an experienced TRT provider ensures your injection protocol is tailored to your needs and optimized based on your body’s response. In accordance, men experience sexual dysfunction at testosterone levels of below 300 ng/dL, and men that have levels of testosterone of approximately 200 ng/dL frequently experience such problems. Although testosterone has been found to be effective at improving sexual function in postmenopausal women, the doses employed have been supraphysiological. Testosterone therapy is effective in the short-term for the treatment of hypoactive sexual desire disorder (HSDD) in women. The United States Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone supplement have been established for low testosterone levels due to aging. Similar to IM injections, periodic monitoring of the patients for risks and benefits should continue as recommended by clinical practice guidelines (1). Patients should be informed that currently, data and experience with SC testosterone therapy both are limited. IM injections of long-acting testosterone esters (cypionate or enanthate) are cost-effective and result in physiological and predictable on-treatment serum testosterone levels, particularly when smaller doses are administered weekly (18). To date, limited data suggest that SC administration of testosterone enanthate and cypionate results in stable and predictable on-treatment concentrations, has good acceptability among patients, and can be self-administered more easily than IM injections. Because of the longer absorption time, it was introduced as an option to minimize peaks and troughs in serum testosterone levels after dosing, as well as to reduce the frequency of injections in men with organic androgen deficiency who require long-term testosterone therapy. Testosterone replacement therapy can improve many of the symptoms of low testosterone (male hypogonadism). This includes monitoring your testosterone level and getting other blood tests to make sure TRT isn’t harming your health. If you stop taking testosterone, your body will have to recover its ability to make testosterone again. With TRT, you take a manufactured form of testosterone to regulate your levels. Before starting TRT, your healthcare provider will make sure low testosterone is an accurate diagnosis. Testosterone replacement therapy (TRT) can help improve the symptoms of low testosterone due to male hypogonadism. BDPT does not provide medical advice, diagnosis, or treatment.